Compare Gilead Sciences, Inc. (GILD) vs Global E Online Ltd (GLBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Global E Online Ltd — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Global E Online Ltd trades at $40.39 (market cap $6.75B). The key difference: Gilead Sciences, Inc. is far larger — about 27× Global E Online Ltd's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Global E Online Ltd for 21 Days on average.
| GILD | GLBE | |
|---|---|---|
Market Cap | $182.40B | $6.75B |
Volume | 4,469,821 | 1,468,708 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $42.36 |
52-Week Low | $116.74 | $27.54 |
Typical Hold Time | 111 Days | 21 Days |
Enterprise Value | $205.46B | $6.24B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
GLBE trades at $40.15, up 3.05% today, with a bullish technical setup supported by moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates, and raised its full-year 2026 outlook. Revenue grew 39% year-over-year, and adjusted EBITDA margin expanded to 20.9%. Recent news includes the appointment of a new Chief Revenue Officer and significant insider selling by executives.
The outlook is positive, driven by robust revenue growth and margin expansion, with a consensus price target of $48.86 implying 22% upside. Risks include high valuation multiples and recent insider selling. Analyst consensus is strongly bullish with 14 buy ratings, but investors should monitor competitive pressures and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →
